Primary tabs
Revisions allow you to track differences between multiple versions of your content, and revert back to older versions.
| Revision | Operations | |
|---|---|---|
| 10-26-23 by kaipe | current revision | |
| 10-26-23 by kaipe | ||
| 10-26-23 by kaipe Added language that some experts may recommend dose adjustment in renal dysfunction, added dosing for Mycobacterial infections. | ||
| 02-17-22 by [email protected] | ||
| 07-26-21 by conan.macdougal... | ||
| 02-16-21 by conan.macdougal... | ||
| 02-16-21 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 07-10-20 by [email protected] | ||
| 04-21-20 by ucsf_admin | ||
| 04-21-20 by ucsf_admin | ||
Dosing: Adult Antimicrobial Dosing, Non-dialysis
| Indication | Dose | Notes |
|---|---|---|
| All Indications | 600 mg IV/PO q12h | No renal dose adjustment* |
| Mycobacterial Infections | 600 mg IV/PO q24h | No renal dose adjustment |
*In clinically stable patients with CrCl <30 mL/minute and an anticipated treatment course >10 days, some experts suggest reducing dose to 300 mg IV/PO twice daily after 72 hours to reduce the risk of thrombocytopenia. Therapeutic drug monitoring may be utilized. Contact ID or ID pharmacy for assistance.
Dosing: Antimicrobial Dosing in Intermittent & Continuous Hemodialysis
| Indication | Dose | Notes |
|---|---|---|
| All Indications | 600 mg IV/PO q12h | No dose adjustment in hemodialysis |
Dialysis Notes
Intermittent HD assumes high-flux hemodialysis. CRRT assumes CVVHD with ultrafiltration rate 2L/h and residual native GFR < 10 mL/min. For detailed view of dialysis dosing and evidence, see Dosing in Hemodialysis document.
All use in pediatric patients at UCSF requires approval from the Pediatric Antimicrobial Stewardship Program or pediatric ID physician
All use at ZSFG requires approval by ID pharmacist or ID fellow.